Chemical Component Summary | |
---|---|
Name | bromoergocryptine |
Synonyms | bromocriptine |
Identifiers | n/a |
Formula | C32 H40 Br N5 O5 |
Molecular Weight | 654.594 |
Type | NON-POLYMER |
Isomeric SMILES | CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5Cc6c7c(cccc7[nH]c6Br)C5=C4)C)O |
InChI | InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 |
InChIKey | OZVBMTJYIDMWIL-AYFBDAFISA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 83 |
Chiral Atom Count | 6 |
Bond Count | 89 |
Aromatic Bond Count | 10 |
Drug Info: DrugBank
DrugBank ID | DB01200 |
---|---|
Name | Bromocriptine |
Groups |
|
Description | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above. |
Synonyms |
|
Brand Names |
|
Indication | For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome. |
Categories |
|
ATC-Code |
|
CAS number | 25614-03-3 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Dopamine D2 receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | agonist |
Dopamine D3 receptor | MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV... | unknown | agonist |
5-hydroxytryptamine receptor 1D | MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITL... | unknown | agonist |
Alpha-2A adrenergic receptor | MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFG... | unknown | agonist |
5-hydroxytryptamine receptor 1A | MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA... | unknown | agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL493 |
PubChem | 31101 |
ChEMBL | CHEMBL493 |
ChEBI | CHEBI:3181 |